Events & Presentations

Investors

Events & Presentations

Upcoming Events
Date Event Details Remind Me
Mar 26, 2019 4:35 PM EDT
Oligonucleotide & Precision Therapeutics (OPT) Congress
James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “siRNA Clinical Development Based on the TRiMTM Platform”
Cambridge, MA
Mar 27 - Mar 30, 2019
CSHL Meeting: RNA & Oligonucleotide Therapeutics
Dr. Hamilton will deliver an oral presentation titled, “Cardiovascular and lipid disorders - A next frontier for TRiMTM RNAi”
Cold Spring Harbor, NY
Apr 3, 2019 8:00 AM EDT
AACR Annual Meeting 2019
So Wong, Ph.D., Arrowhead’s director of oncology, will deliver a poster presentation titled, “Optimizing the potency and dosing design for ARO-HIF2: An RNAi therapeutic for clear cell renal cell carcinoma”
Apr 10, 2019
The EASL International Liver Congress 2019

Oral Presentation:
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg <100 IU/mL threshold

  • Presentation Reference: PS-080
  • Session: Parallel session: Hepatitis B - drug development
  • Date and Time: April 12, 2019 at 5:45 p.m. CET
  • Authors: Man-Fung Yuen, et al.

Poster Presentation:
Reduction of hepatic Z-alpha1 antitrypsin by RNA interference (RNAi) prevents and reverses liver disease including hepatic mitochondrial injury in the PiZ mouse model

  • Presentation Reference: FRI-446
  • Session: Poster: Rare liver diseases (including pediatric and genetic)
  • Session Date and Time: April 12, 2019 from 9 a.m. to 5 p.m. CET
  • Authors: Christine Wooddell, et al.
Archived Events
Date Event Details
Nov 12, 2018
The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)

First Results with RNA interference (RNAi) in Chronic Hepatitis B (CHB) Using ARO-HBV

  • Publication Number: LB-25
  • Session: Late-Breaking Poster Session
  • Session Date and Time: November 12, 2018 from 8:00 AM to 5:30 PM PT
  • Location: Moscone Center North/South Building, Hall C
  • Authors: Dr. Edward J. Gane, et al.


A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum Alpha-1 Antitrypsin levels in Normal Adult Volunteers

  • Publication Number: LB-9
  • Session: Late-Breaking Poster Session
  • Session Date and Time: November 12, 2018 from 8:00 AM to 5:30 PM PT
  • Location: Moscone Center North/South Building, Hall C
  • Authors: Dr. Christian Schwabe, et al.
Nov 9, 2018
The Search for HBV / HDV Cure: Challenges for Industry
San Francisco
November 9, 11:15 a.m. PST – Dr. Given will deliver an oral presentation titled, “AROHBV1001 Results Update”
Nov 7, 2018
International HBV Cure Workshop 2018
Toronto
November 7, 3:35 p.m. EST – Bruce Given, M.D., Arrowhead’s chief operating officer, will deliver an oral presentation titled, “Clinical update on reducing HBV virus and antigen production using RNAi”
Nov 6, 2018
BIT’s 16th Annual Congress of International Drug Discovery Science and Technology
Jinan, China
November 6, 11:20 a.m. CST – Zhen Li, Ph.D., Arrowhead’s senior vice president of chemistry and non-clinical development, will deliver a keynote presentation titled, “Discovery and Development of Arrowhead Clinical Candidates ARO-AAT and ARO-HBV”
Oct 18, 2018 11:15 AM MDT
North American Cystic Fibrosis Conference
Denver, CO
Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver a poster presentation titled, “A novel targeted RNAi molecule (TRiM™) delivery platform for the therapeutic inhibition of ENaC in cystic fibrosis lung disease”
Oct 16, 2018 1:00 PM EDT
Arrowhead Analyst R&D Day 2018
New York, NY
Arrowhead management and external key opinion leaders will discuss Arrowhead’s emerging pipeline of RNAi therapeutics
Oct 9, 2018 1:00 PM EDT
Chardan 2nd Annual Genetic Medicines Conference
New York, NY
Bruce Given, M.D., Arrowhead’s chief operating officer, will participate in a fireside chat.
Oct 5, 2018 7:00 AM EDT
2018 International HBV Meeting - The Molecular Biology of Hepatitis B
Taormina, Italy
October 5, 1:00 p.m. CEST –Christine Wooddell, Ph.D., Arrowhead’s director of liver targeting, will deliver a poster presentation titled, “Gene expression analysis during and after RNAi treatment of chronically HBV infected chimpanzees”
Oct 4, 2018 8:30 AM EDT
Arrowhead/Janssen Collaboration Call
Oct 2, 2018 10:55 AM EDT
2018 Cantor Fitzgerald Global Healthcare Conference
New York, NY
Christopher Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will deliver a corporate presentation